Since December 2019, a new agent, the SARS-Cov-2 coronavirus has been rapidly spreading from China to other countries causing an international outbreak of respiratory illnesses named COVID-19. In France, the first cases have been reported at the end of January with more than 60000 cases reported since then. A significant proportion (20-30%) of hospitalized COVID-19 patients will be admitted to intensive care unit. However, few data are available for this special population in France. We conduct a large observational cohort of ICU suspected or proven COVID-19 patients that will enable to describe the initial management of COVID 19 patients admitted to ICU and to identify factors correlated to clinical outcome.
Study Type
OBSERVATIONAL
Enrollment
1,003
No intervention
CHU Nimes
Nîmes, France
Mortality at day 28
Mortality at day 28
Time frame: day 28
severe complications
severe complications (pulmonary embolism, acute kidney injury, myocarditis, cardiac arrest, liver failure, ventilator associated pneumonia) Yes / No
Time frame: up to day 28
Imaging
Delay in imaging in hours
Time frame: day 1
Delay in Microbiological diagnosis
delay in microbiological diagnosis in hours
Time frame: day 1
Antiviral therapy
Antiviral therapy Yes / no
Time frame: up to day 28
Antibiotic therapy
Antibiotic therapy Yes / No
Time frame: day 28
Covid-19 treatments
Covid-19 treatments Yes / No
Time frame: up to day 28
Patients receiving renal replacement therapy
number
Time frame: up to day 28
Patients receiving mechanical ventilation
number
Time frame: up to day 28
Vital status
Patient alive at day 28 : yes / No
Time frame: day 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.